Here, a quantitative real-time polymerase chain reaction-based protocol is presented for the determination of the native micro-RNA content (absolute/relative) of lipoprotein particles. In addition, a method for increasing the micro-RNA level, as well as a method for determining the cellular uptake rate of lipoprotein particles, is demonstrated.
Lipoprotein particles are predominately transporters of lipids and cholesterol in the bloodstream. Furthermore, they contain small amounts of strands of noncoding microRNA (miRNA). In general, miRNA alters the protein expression profile due to interactions with messenger-RNA (mRNA). Thus, knowledge of the relative and absolute miRNA content of lipoprotein particles is essential to estimate the biological effect of cellular particle uptake. Here, a quantitative real-time polymerase chain reaction (qPCR)-based protocol is presented to determine the absolute miRNA content of lipoprotein particles—exemplified shown for native and miRNA-enriched lipoprotein particles. The relative miRNA content is quantified using multiwell microfluidic array cards. Furthermore, this protocol allows scientists to estimate the cellular miRNA and, thus, the lipoprotein particle uptake rate. A significant increase of the cellular miRNA level is observable when using high-density lipoprotein (HDL) particles artificially loaded with miRNA, whereas incubation with native HDL particles yields no significant effect due to their rather low miRNA content. In contrast, the cellular uptake of low-density lipoprotein (LDL) particles—neither with native miRNA nor artificially loaded with it—did not alter the cellular miRNA level.
Lipoprotein particles are composed of a monolayer of amphiphilic lipids and cholesterol enclosing a core of cholesteryl esters and triglyceride fats. The whole particle is stabilized by membrane-embedded apolipoproteins, which define the particle’s biological functionality. Lipoprotein particles can be distinguished according to their respective increasing density and, thus, decreasing size, namely as very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), LDL, and HDL particles. Despite the transportation of water-insoluble components in the bloodstream, it has been demonstrated that HDL particles carry noncoding strands of miRNA1,2. Micro-RNAs are a class of short (usually two dozen nucleotides) RNA strands, which degrade intracellularly complementary mRNA strands and, thereby, alter the expression profile of certain proteins3,4,5,6. Furthermore, alterations of the miRNA profile have been found in a variety of diseases and, thus, the profile is applicable as a biomarker for diagnosis and prognosis. The extracellular transport of miRNAs between cells via lipoprotein particles may serve as an additional mechanism for intercellular mRNA level modulation. To quantitatively estimate the biological effect, knowledge regarding the absolute and relative miRNA content of lipoprotein particles is needed.
Quantitative real-time PCR is a suitable and relatively quick method to gain this information. Hence, the relative quantification (RQ) value can be calculated, and relative differences between different samples and lipoprotein fractions are estimable. Multiwell microfluidic array cards are a fast and easy-to-use method to determine the relative presence (equates to the RQ value) of miRNAs in a sample. Multiwell microfluidic array cards consist of 96 or 384 individual reaction chambers for individual qPCR reactions embedded in a microfluidic device. Each chamber contains the required hydrolysis probe and specific qPCR primers for one individual miRNA. The advantages are a short handling time due to standardization, a simple workflow, and a reduced number of pipetting steps. Moreover, the required sample volume is minimized. In contrast to the relative quantification, the absolute miRNA content requires a comparison of qPCR sample results with standard curves of known absolute numbers of miRNA strands. It should be noted that, due to their relatively low miRNA content, standard and, moreover, even single-molecule sensitive imaging techniques are not feasible—the artificial enrichment of lipoprotein particles with miRNA is inevitable to study cellular lipoprotein particle interaction and miRNA transfer. Regarding this, delipidation of the HDL particle followed with subsequent relipidation7 allows the incorporation of and, thus, enrichment with miRNA strands. Similar enrichment of LDL particles with miRNA is not feasible due to the hydrophobicity of the apoB-100 protein, which is the main constituent of the LDL particle. However, by addition of the polar solvent dimethyl sulfoxide (DMSO), which is able to penetrate lipid membranes, LDL particles can be artificially loaded with miRNA strands as well.
High-speed atomic force microscopy (HS-AFM) is a powerful tool for the characterization of biological specimens offering subnanometer spatial and subsecond temporal resolution8. Hence, it is a well-suited technique for the quality control of modified lipoprotein particles as native/reconstituted/labeled lipoprotein particles can be imaged under a near-physiological environment.
Here, a qPCR-based protocol is presented step-by-step to determine the absolute/relative miRNA content of lipoprotein particles and cell samples, which allows an estimation of the cellular lipoprotein particle uptake rate. Moreover, a method for the enrichment of lipoprotein particles with miRNA is demonstrated. This method may be adapted for the general manipulation of lipoprotein content and, hence, demonstrates the applicability of lipoprotein particles as targets for drug delivery.
Blood donations have been approved by the Ethics Committee, Medical University of Vienna (EK-Nr. 511/2007, EK-Nr. 1414/2016). Nomenclature is according to the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE)9 guidelines.
1. Lipoprotein particle isolation from human blood
2. Synthetic miRNA aliquots
NOTE: When handling RNA oligonucleotides, work RNase-free. Work only with fresh, disposable plastic consumables and always wear gloves, which should be changed frequently. Use only nuclease-free solutions. Always work on ice.
3. Reconstitution of HDL particles
4. Labeling of LDL particles
5. Quality control of reconstituted/labeled lipoprotein particles
NOTE: For quality control, the diameter and general shape of lipoprotein particles can be determined using, for instance, AFM or electron microscopy (EM). Here, HS-AFM is used to measure the size distribution of native/reconstituted/labeled lipoprotein particles.
6. Cell culture
7. miRNA extraction from cell and lipoprotein particle samples
NOTE: The extraction of miRNA from cells is performed using the miRNA extraction kit with the following modifications.
8. Reverse transcription
NOTE: The reverse transcription of miRNA is performed using a reverse transcription kit with the following modifications.
9. qPCR
10. Calculation of miRNA content
11. Multiwell microfluidic arrays
A general scheme of lipoprotein particle isolation
Figure 1 shows the general scheme of lipoprotein particle isolation starting from whole blood, using sequential flotation ultracentrifugation16. If desired, other lipoprotein particle fractions like VLDL and IDL particles can be harvested during this protocol. The fixed-angle titanium rotor in combination with polypropylene quick-seal tubes is suitable to withstand the centrifugation forces. To avoid tube collapse, it is important to avoid air bubbles in the tube. Centrifugation is carried out at 4 °C to minimize protein degradation. Usually starting from plasma (60-80 mL per donor) of pooled blood donations of three volunteers, a yield of LDL and HDL particle solution volumes of 3 mL each with concentrations in the range of 1-3 mg/mL can be expected. The whole procedure, starting from blood donation, took around 7 days.
Figure 1: Flowchart of lipoprotein isolation. Centrifuge blood from healthy volunteers in vacuum container tubes and collect plasma (upper phase). After the adjustment of its density to ρ = 1.019 g/mL using KBr, centrifuge the solution at 214,000 x g for 20 h at 4 °C. After the adjustment of the density of the bottom fraction to ρ = 1.063 g/mL using KBr, centrifuge the solution again at 214,000 x g for 20 h at 4 °C. Store the upper fraction containing LDL particles temporary at 4 °C. After the adjustment of the density of the bottom fraction to ρ = 1.220 g/mL using KBr, centrifuge the solution twice at 214,000 x g for 20 h at 4 °C. Collect the upper fraction containing HDL particles, dialyze both the HDL and LDL particle solutions and exchange the buffer after 1, 2, and 4 h. After 24 h, determine the protein concentration and store the samples under inert gas at 4 °C. Please click here to view a larger version of this figure.
Reconstitution of HDL particles
The reconstitution of HDL particles was performed according to a protocol previously published by Jonas7. The first step was the delipidation of HDL particles as shown in Figure 2A, followed by the second step of relipidation (i.e., reconstitution) as shown in Figure 2B, using lipid PC, CO, and C in addition to a mixture of miRNA and spermine. We chose human mature miR-223 and miR-155 because miR-223 shows a high abundance and miR-155 is rare in lipoprotein particles17. Usually, both steps are performed on two sequential days. During reconstitution, other lipophilic and/or amphiphilic components could be added as desired. The complete evaporation of ethanol/diethyl ether and methanol/chloroform solvent of PC, CO, and C was critical. The last step—as shown in Figure 2C—was the dialysis procedure to separate reconstituted HDL particles (rHDL) from free lipids/miRNA/detergent. This took an additional 1-2 days. The addition of absorbent beads to the dialysis solution kept the density gradient along the dialysis membrane constant. A yield of 50% of rHDL particles can be expected.
Figure 2: Flowchart of HDL particle reconstitution. (A) Delipidation: Mix the HDL particle solution with precooled ethanol/diethyl ether and incubate at -20 °C for 2 h. After discarding the supernatant, resuspend the pellet and repeat the procedure. Dry the pellet with N2 gas and resuspend it in buffer A. After the determination of the concentration, store the delipidated HDL under inert gas atmosphere at 4 °C. (B) Reconstitution: After mixing phosphatidyl-choline (PC), cholesteryl oleate (CO), and cholesterol (C), evaporate the solvent using N2 gas while rotating the tube. Incubate the miRNA aliquot with spermine solution for 30 min at 30 °C, add sodium deoxycholate and resuspend the dried lipid film. Stir the sample for 2 h at 4 °C, add the delipidated HDL solution, and stir the sample again, this time overnight at 4 °C under inert gas atmosphere. (C) Dialysis: Transfer the solution from panel B containing reconstituted HDL (rHDL) particles to a dialysis membrane chamber (molecular weight cut-off: 20 kDa) and dialyze against PBS and absorbent beads at 4 °C. Exchange the buffer and the beads after 1 h and 2 h. Recover the rHDL particle solution after 24 h, determine the concentration, and store the sample under inert gas atmosphere at 4 °C. Please click here to view a larger version of this figure.
Labeling of LDL particles
The labeling of LDL particles with miRNA (Figure 3) as demonstrated for HDL particles was not feasible due to the hydrophobicity of the apoB-100 protein, which is the main constituent of the LDL particle. DMSO was used for the penetration of the lipid monolayer of the LDL particle and, thus, mediated the miRNA association. The whole procedure took 1-2 days with a yield close to 100%.
Figure 3: Flowchart of LDL particle labeling. Incubate the miRNA aliquot with spermine solution for 30 min at 30 °C and add DMSO and LDL buffer. Incubate LDL sample wit LDL buffer for 10 min on ice and add miRNA/spermine/DMSO mixture. After incubation at 40 °C for 2 h, transfer the solution into a dialysis membrane chamber (molecular weight cut-off: 20 kDa) and dialyze against PBS and absorbent beads at +4 °C. Exchange buffer and beads after 1 & 2 h. Recover labeled LDL particle solution after 24 h, determine the concentration and store under inert gas atmosphere at +4 °C. Please click here to view a larger version of this figure.
Quality control of lipoprotein particles
HS-AFM can be used to examine the size and shape of native and reconstituted/labeled lipoprotein particles on mica. Just before use, mica has to be freshly cleaved (use adhesive tape to remove the upper layer[s]) in order to provide a clean and flat surface. When incubating HDL/LDL particles on mica, the dilution factor (and/or the incubation time) needs to be adjusted to observe individual particles. Clusters do not allow a determination of particle dimensions. HDL particles are mobile on mica. When using conventional AFM instead of HS-AFM, the immobilization protocol needs to be adapted accordingly (buffer, surface coating) to reduce the lateral particle mobility. While scanning the sample, the imaging force has to be kept low (tapping mode) to avoid any deformation of the particles, which will consequently affect the measured values. For data analysis, particles were detected via a threshold algorithm (e.g., in Gwyddion: Grains > Mark by threshold) and their height was determined with respect to the mica surface. Measuring the particles’ height is the most precise way to determine particle sizes, as the apparent lateral dimensions are broadened by the tip shape (see exemplary images in Figure 4). Probability density functions (pdfs) of particle heights were calculated for statistical evaluation and comparison of size distributions of the various lipoprotein particles. A comparison of native and miRNA-labeled LDL particles as shown in Figure 4 makes it possible verify the principal similarity between labeled and nonlabeled (i.e., native) lipoprotein particles (labeled LDL particles without the addition of miRNA/spermine mixtures are shown as a control for the labeling procedure itself). The whole procedure took approximately 1 day.
Figure 4: Flowchart and representative results of HS-AFM measurements. Dilute the HDL/LDL particle sample in PBS (1:102-1:103) and incubate it on freshly cleaved mica for 5 min, followed by a careful rinse with PBS to remove free (not electrostatically adsorbed) particles. Perform HS-AFM imaging and check the particle density on the surface. Carry out the measurements in PBS at room temperature. The top image of this figure shows a too high particle density; the bottom image is suitable for analysis. The height of single particles was analyzed after thresholding and native (black curve) and reconstituted/labeled (red and green curve) particles were compared in a statistical evaluation. The scale bar = 100 nm. This figure has been modified from Axmann et al.19. Please click here to view a larger version of this figure.
miRNA extraction, reverse transcription, and qPCR
The extraction of miRNA from native/artificially enriched lipoprotein or cell samples was performed using a miRNA extraction kit as shown in Figure 5A. Hereby, an RNase-free environment was critical. This step took approximately 1 h. Reverse transcription of the extracted miRNA sample (Figure 5B) was performed using standard biochemical procedures as described by the manufacturer. This step took approximately 1.5 h. Finally, the amount of cDNA obtained during the last step was determined using qPCR (Figure 5C). A standard curve, which relates the obtained cq values to the absolute miRNA strand number, yielded the absolute miRNA content of the initial sample. This took approximately 2.5 h.
Figure 5: Flowchart of miRNA extraction, reverse transcription, and qPCR. (A) miRNA extraction: Mix the sample with lysis reagent and lyse it via aspiration using a syringe. Incubate for 5 min and add CHCl3. Shake vigorously for 15 s and incubate for 3 min. After centrifugation at 1,200 x g for 15 min at 4 °C, collect the top phase and mix it with ethanol. Transfer the solution to a spin column (maximum volume <700 µL) and centrifuge it at 8,000 x g for 15 s. Discard the eluent and repeat the last step with the rest of the solution. Add the first washing buffer and centrifuge at 8,000 x g for 15 s. Discard the eluent, add the second washing buffer, and centrifuge at 8,000 x g for 15 s. Repeat the last step with a centrifugation time of 2 min. Further dry the membrane via centrifugation at maximum speed for 1 min. Elute the miRNA with H2O and centrifuge at 80,000 x g for 1 min. Store the extracted miRNA sample at -20 °C. (B) Reverse transcription: Thaw the 10x buffer, H2O, dNTP mix, inhibitor, and enzyme on ice and prepare the master mix. Add the extracted miRNA from panel A to the master mix and the reverse transcription primer and perform reverse transcription using a thermocycler machine. Store the cDNA sample at -20 °C. (C) qPCR: Thaw the supermix, H2O, and primer on ice and prepare the master mix. Add the cDNA from panel B to the master mix and perform qPCR. Analyze the data to obtain cq values and calculate the absolute miRNA content of the sample (see Figure 6 and the representative results for details). Please click here to view a larger version of this figure.
Absolute miRNA content and transfer rate
The absolute miRNA content of native and artificially enriched HDL and LDL particles was calculated from the cq values of the samples and a standard curve of the respective miRNA as shown in Figure 6. Figure 6A shows data as calculated by the analysis software (with activated DynamicTube normalization [for the compensation of different background levels using the second derivative of each sample trace] and Noise slope correction [normalization to the noise level]). cq values of standard curves were determined using the Auto-find threshold function of the software package on the normalized fluorescence signal measured by the qPCR machine. Hereby, the software maximized the R-value of the fit of the standard curve. The threshold level was kept constant for each specific miRNA sample analysis. Subsequently, the cq values were plotted as a function of the number of miRNA strands, and a regression line was calculated. Sample cq values were determined with the same threshold level as shown in Figure 6B; reaction efficiency differences between different qPCR runs were compensated automatically by the software using one additional calibration curve sample included in each run. Using the regression line equation, the unknown amount of miRNA in the sample could be calculated. The lipoprotein particle number was estimated from the initial protein concentration and its average molecular weight (MWHDL ~250 kDa). Thereby, no lipid contribution to the molecular weight was assumed—thus, the number of miRNA strands per lipoprotein particle was slightly overestimated. Moreover, a 100% recovery rate of miRNA during the miRNA extraction step was assumed. Furthermore, the miRNA content of the cells before and after the incubation with HDL particles was determined and the miRNA transfer rate was calculated as shown in Figure 6C.
Figure 6: Flowchart of calculation of the absolute miRNA content and transfer rate. (A) Standard curve for miR-155: A miR-155 aliquot (100 µL, 10 µM) was serially diluted with RNA-free water as indicated. qPCR yielded cq values for each serial dilution sample (measured twice) using the Auto-find threshold function of the software package. Negative control experiments (without the addition of miRNA) yielded cq values of >35. Data points of cq values as function of the number of miRNA strands per sample volume (calculated from the initial concentration and the serial dilutions) were fitted with the presented equation (red line, right image), yielding M = -3.36 and B = 42.12. The determined PCR efficiency was 0.98. The error bars were calculated from the results of experimental repetitions and were smaller than the diameter of the data point circle. (B) cq values of native/artificially enriched HDL particles were determined with the same threshold level as determined in panel A and converted to the number of miRNA strands in the qPCR sample volume. The absolute ratio of miRNA of the original sample was calculated from the number (concentration) of HDL particles in the sample volume (3.2 x 1011 particles). (C) Cell samples (cell line ldlA7-SRBI) were incubated for 16 h with artificially enriched HDL particles (50 µg/mL) and analyzed similarly. The determined cq values were 22.5, 22.5, and 19.3 for cells only, for cells incubated with native HDL, or for cells incubated with rHDL particle solution (both 50 µg/mL), respectively. These values were converted to the number of miRNA strands as done in panel B. The number of miRNA strands after incubation (7.3 x 106) were corrected by subtraction of the number of miRNA strands before incubation (8.6 x 105). The result was divided by the number of cells in the sample volume (3,100), the miRNA-particle-ratio (1.5 x 10-4), and the incubation time period (16 h). This yielded the transfer rate of lipoprotein particles via miRNA uptake (240 HDL particle uptake events per cell and second). This figure has been modified from Axmann et al.19. Please click here to view a larger version of this figure.
Multiwell microfluidic array
Due to small yields of miRNA extraction, reverse transcription of the extracted miRNA was followed by a preamplification step. Finally, qPCR, as shown in Figure 6, was performed. For all steps, standard biochemical procedures were used as described by the manufacturer. Here, a part of the global miRNA profile on HDL particles of uremic patients recruited for a study on the influence of CRF on cholesterol efflux from macrophages18 is shown. In this study, the cholesterol acceptor capacity of HDL or serum in—besides others—17 young adult uremic patients (CKD stages 3-5) and 14 young adult hemodialysis patients without associated diseases and matched controls was measured. To analyze the data, default settings were used (maximum allowable CT value: 40.0, including maximum CT values in calculations and excluding outliers among replicates). P-values were adjusted using Benjamini-Hochberg false discovery rate (correction of the occurrence of false positives), and as normalization method, Global Normalization was selected, which finds the common assays among all samples to use its median CT for normalization. In the representative results, some RQs of miRNAs isolated from HDLs of uremic patients are depicted (RQs of controls are 1). Obviously, miR-122 and miR-224 are highly expressed in the HDLs of uremic patients. This whole step took approximately 1 day.
Figure 7: Flowchart and representative results of the multiwell microfluidic array. After the miRNA extraction as shown in Figure 5A, mix the miRNA sample with reverse transcription primer and a master mix containing 10x buffer, H2O, dNTP mix, inhibitor, MgCl2, and enzyme. After incubation on ice for 5 min, perform the reverse transcription using a thermocycler machine. Add the preamplification master mix, incubate for 5 min on ice, and perform preamplification using a thermocycler machine. Add 0.1x TE (pH 8.0) and mix an aliquot with PCR master mix and H2O. Pipette the PCR reaction mix into the fill port of the multiwell microfluidic array and spin twice at 3,000 x g for 1 min each. Perform qPCR using a PCR system and analyze the data to yield RQ values (here, the figure shows RQ values of HDL particles of uremia patients in comparison to a healthy control group18). Please click here to view a larger version of this figure.
Here, the isolation of lipoprotein particle fractions from human blood and the determination of their individual miRNA content is described step-by-step. It is critical to work in an RNase-free environment while handling isolated and synthesized miRNA—particle-embedded miRNA is obviously sheltered from enzymatic degradation. As the miRNA/particle ratio of native lipoprotein particles is rather low, artificial enrichment with miRNA is required to study the holo particle uptake of cells. Thereby, the reconstitution of HDL particles as described previously7 is modified to incorporate miRNA strands. Additionally, the separation of the lipid and protein fraction during this procedure allows scientists to examine lipid- and protein-associated components of the lipoprotein particle19. In a similar way, the labeling procedure of LDL particles is adapted. Interestingly, the addition of spermine—a natural stabilizer of nucleotides—did not influence the miRNA/particle ratio. It should be noted that, in principle, the method allows the infolding of other substances than miRNA within a lipoprotein particle. Of course, there is a limit with regard to the physical size of the substance based on the overall size of HDL (diameter: 5-12 nm) and LDL particles (diameter: 18-25 nm).
Concerning the quality control of reconstituted/labeled lipoprotein particles, HS-AFM is an applicable method to characterize HDL/LDL particles at the single particle level. In comparison to EM, it allows for shorter preparation times and near-physiological conditions (wet, room temperature).
Due to its inherent sensitivity and amplification, qPCR is the method of choice to detect low miRNA concentrations. Alternatively, single-molecule sensitive fluorescence microscopy, which is able to detect even individual molecules, would not be suitable due to the low concentrations of, for instance, fluorescently labeled miRNA strands per particle. Thus, the ratio of miRNA strands per native lipoprotein particle has been found to be 10-8. Artificial enrichment increases the ratio by a factor of 10,000, which facilitates the estimation of the cellular lipoprotein uptake rate (no significant difference is detected using native lipoprotein particles 19). The high sensitivity of qPCR makes it possible to determine this uptake rate by measuring the number of miRNA strands after the incubation time and the miRNA/particle ratio. It should be noted that the calculated value ignores cellular degradation and release of miRNA and, thus, represents at least a lower limit for the lipoprotein particle uptake ratio.
In the future, the method can be adapted to transfer pharmaceutical substances (notably also lipophilic ones) in cells and correlate their biological effect to the intracellular concentration (determined via the uptake rate of lipoprotein particles).
The authors have nothing to disclose.
This work was supported by the Austrian Science Fund Project P29110-B21, the “Hochschuljubiläumsstiftung der Stadt Wien zur Förderung der Wissenschaft” Project H-3065/2011, the European Fund for Regional Development (EFRE, IWB2020), the Federal State of Upper Austria, and the “Land OÖ Basisfinanzierung”.
Ultracentrifuge | Beckman | Optima L-100 XP | Lipoprotein isolation |
Ultracentrifuge rotor | Beckman | TI 55.2 | Lipoprotein isolation |
Vacutainer (EDTA) | Becton Dickinson | 366643 | Lipoprotein isolation |
Kaliumbromid | Sigma Aldrich | 2110 | Lipoprotein isolation |
Ultracentrifuge tubes | Beckman | 342414 | Lipoprotein isolation |
Ultracentrifuge tube sealer | Beckman | 342428 | Lipoprotein isolation |
Sodiumchlorid | Carl Roth GmbH | P029.2 | Lipoprotein isolation |
EDTA | Fisher Scientific | D/0650/50 | Lipoprotein isolation |
Dialysis tubes, MWCO 12 – 14k | Spectra | 132700 | Lipoprotein isolation |
synthetic miRNA | microSynth | – | synthetic miRNA |
TRIS buffer pH 7 | Ambion | AM9850G | synthetic miRNA |
TRIS buffer pH 8 | Ambion | AM9855G | synthetic miRNA |
sterile tubes | Carl Roth GmbH | ENE8.1 | synthetic miRNA |
Photometer | Eppendorf | Eppendorf Biophotometer | Bradford assay |
Cuvette | Carl Roth GmbH | XK20 | Bradford assay |
Coomassie G-250 Stain | BioRad GmbH | 161-0786 | Bradford assay |
Sodiumchlorid | Carl Roth GmbH | 3957.1 | Delipitation |
EDTA | Fluka Analytical | 03690-100ML | Delipitation |
TRIS buffer pH 8.0 | Ambion | AM9855G | Delipitation |
Ethanol 100% | AustrAlco | Ethanol Absolut 99.9% | Delipitation |
Diethyl ether | Carl Roth GmbH | 3942.1 | Delipitation |
Centrifuge | Thermo Scientific | Multifuge X3R | Delipitation |
Chloroform | Carl Roth GmbH | 3313.1 | Reconstitution |
Methanol | Carl Roth GmbH | 4627.1 | Reconstitution |
Phosphatidylcholine | Sigma Aldrich GmbH | P3556-25mg | Reconstitution |
Cholesterol oleate | Sigma Aldrich GmbH | C-9253-250mg | Reconstitution |
cholesterol | Sigma Aldrich GmbH | C8667-500mg | Reconstitution |
glass tubes | Carl Roth GmbH | K226.1 | Reconstitution |
spermine | Sigma Aldrich GmbH | S3256-1G | Reconstitution |
Thermomixer | Eppendorf | Thermomixer comfort | Reconstitution |
Sodium deoxycholate | Sigma Aldrich GmbH | 3097-25G | Reconstitution |
Magnetic stir bar | Carl Roth GmbH | 0955.2 | Reconstitution |
100µL micropipettes | Carl Roth GmbH | A762.1 | Reconstitution |
PBS | Carl Roth GmbH | 9143.2 | Dialysis |
Amberlite XAD-2 beads | Sigma Aldrich GmbH | 10357 | Dialysis |
Slide-A-Lyzer casette (cut-off 20 kDa) | Thermo Scientific | 66003 | Dialysis |
Syringe | Braun | 9161406V | Dialysis |
Syringe needle | Braun | 465 76 83 | Dialysis |
EGTA | Carl Roth GmbH | 3054.2 | Labeling of LDL particles |
DMSO | life technologies | D12345 | Labeling of LDL particles |
Atomic Force Microscope | RIBM | SS-NEX | Quality control of reconstituted/labeled lipoprotein particles |
Muscovite Mica (V-1 Grade) | Christine Gröpl | G250-1/V1 | Quality control of reconstituted/labeled lipoprotein particles |
AFM Cantilever | Nanoworld | USC-F1.2-k0.15 | Quality control of reconstituted/labeled lipoprotein particles |
Gwyddion 2.49 | Czech Metrology Institute | http://gwyddion.net | Quality control of reconstituted/labeled lipoprotein particles |
Chamber slides, Nunc Lab-Tek | VWR | 734-2122 | Cell culture |
HBSS | Carl Roth GmbH | 9117.1 | Cell culture |
Cell counter | Omni Life Science GmbH | Casy | Cell culture |
miRNeasy Mini Kit | QIAGEN | 217004 | miRNA extraction |
Centrifuge | Eppendorf | 5415R | miRNA extraction |
20G needle | Braun | Sterican 465 75 19 | miRNA extraction |
5ml syringe | Becton Dickinson | 309050 | miRNA extraction |
PCR cabinet | Esco | PCR-3A1 | Reverse Transcription |
TaqMan Reverse Transcription Kit | Thermo Scientific | 4366596 | Reverse Transcription |
Rnase-free water | Carl Roth GmbH | T143 | Reverse Transcription |
0.2 ml tubes | Brand | 781305 | Reverse Transcription |
Centrifuge | Carl Roth GmbH | Microcentrifuge AL | Reverse Transcription |
Thermocycler | Sensoquest | Labcycler | Reverse Transcription |
TaqMan Primer | Thermo Scientific | – | qPCR |
iTaq Universal probe supermix | BioRad GmbH | 1725131 | qPCR |
PCR machine | Corbett | Rotor-Gene RG-6000 | qPCR |
TaqMan MicroRNA Reverse Transcription Kit | Applied Biosystems | 4366596 | TaqMan Array |
Megaplex RT Primers, Human Pool A v2.1 | Applied Biosystems | 4399966 | TaqMan Array |
TaqMan PreAmp Master Mix | Applied Biosystems | 4391128 | TaqMan Array |
Megaplex PreAmp Primers, Human Pool A v2.1 | Applied Biosystems | 4399933 | TaqMan Array |
TaqMan Universal Master Mix II, no UNG | Applied Biosystems | 4440040 | TaqMan Array |
TaqMan Advanced miRNA Human A Cards | Applied Biosystems | A31805 | TaqMan Array |
Nuclease-free water | Thermo Scientific | R0581 | TaqMan Array |
MgCl2 (25mM) | Thermo Scientific | R0971 | TaqMan Array |
TE, pH 8.0 | Invitrogen | AM9849 | TaqMan Array |
7900HT Fast Real-Time PCR System | Applied Biosystems | 4351405 | TaqMan Array |
TaqMan Array Card Sealer | Applied Biosystems | – | TaqMan Array |